2018
DOI: 10.1097/qai.0000000000001624
|View full text |Cite
|
Sign up to set email alerts
|

Alcohol Use and HIV Disease Progression in an Antiretroviral Naive Cohort

Abstract: Unhealthy alcohol use had no apparent impact on the short-term rate of CD4 count decline among HIV-infected ART naive individuals in Uganda, using biological markers to augment self-report and examining disease progression before ART initiation to avoid unmeasured confounding because of misclassification of ART adherence.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
32
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
8

Relationship

4
4

Authors

Journals

citations
Cited by 33 publications
(33 citation statements)
references
References 48 publications
1
32
0
Order By: Relevance
“…For this analysis, we analyzed baseline data from 2 longitudinal cohorts of adults living with HIV recruited from the Mbarara Regional Referral Hospital's (MRRH) Immune Suppression Syndrome (ISS) clinic in southwestern Uganda. The studies are part of the Uganda–Russia–Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH) Consortium and are described in detail elsewhere (Hahn et al., , ). ISS clinic patients were eligible for the Alcohol Drinking Effects Prior to Treatment (ADEPT) study from 2011 through 2014 if they were ≥18 years, fluent in English or Runyankole (the local language), lived within 60 km of the clinic, and were not yet eligible to initiate HAART.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…For this analysis, we analyzed baseline data from 2 longitudinal cohorts of adults living with HIV recruited from the Mbarara Regional Referral Hospital's (MRRH) Immune Suppression Syndrome (ISS) clinic in southwestern Uganda. The studies are part of the Uganda–Russia–Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH) Consortium and are described in detail elsewhere (Hahn et al., , ). ISS clinic patients were eligible for the Alcohol Drinking Effects Prior to Treatment (ADEPT) study from 2011 through 2014 if they were ≥18 years, fluent in English or Runyankole (the local language), lived within 60 km of the clinic, and were not yet eligible to initiate HAART.…”
Section: Methodsmentioning
confidence: 99%
“…ISS clinic patients were eligible for the Alcohol Drinking Effects Prior to Treatment (ADEPT) study from 2011 through 2014 if they were ≥18 years, fluent in English or Runyankole (the local language), lived within 60 km of the clinic, and were not yet eligible to initiate HAART. Recruitment was targeted to include approximately 50% unhealthy drinkers (defined after study enrollment as Alcohol Use Disorders Identification Test—Consumption (AUDIT‐C) score of ≥3 for women and ≥4 for men, or PEth value ≥50 ng/ml; Hahn et al., ). The Biomarker Research on Ethanol Among Those with HIV (BREATH) study was a cohort study examining changes in alcohol use during the first year of HIV/AIDS care at the MRRH ISS Clinic, conducted from 2011 to 2014.…”
Section: Methodsmentioning
confidence: 99%
“…The primary aim of the ADEPTT study is to estimate the rate of hepatotoxicity to isoniazid (6 months INH) treatment among adults (> = 18 years) who are HIV/LTBI co-infected and are current (prior 3 months) alcohol drinkers and to compare that rate to hepatotoxicity among non-drinkers (abstaining at least one year). We screened PLWH who participated in prior URBAN ARCH studies of alcohol use in the Immune Suppression Syndrome (ISS) clinic of Mbarara Regional Referral Hospital (MRRH) in south-western Uganda from 2010-2017 [25,26]. Eligibility criteria was based on the main ADEPTT study and included: 1) age � 18 years, 2) fluency in English or Runyakole (the local language), 3) HIV-infected on a non-nevirapine containing ART regimen for at least six months, 4) living within 2 hours travel time from the clinic with no plans to move, 5) no evidence of active TB infection based on WHO symptoms criteria, 6) no prior use of TB medicines for treatment and/or prevention of TB, 7) being either a self-reported current (prior 3 month) drinker or abstainer (at least one year since drinking), 8) having alanine aminotransferase [ALT] and aspartate aminotransferase [AST] � 2x of the upper limit of normal (ULN), 9) women who were pregnant.…”
Section: Study Setting and Populationmentioning
confidence: 99%
“…A systematic review and meta-analysis study by Duko et al 2019 [7] showed that the average worldwide prevalence of AUD among patients with HIV/AIDS was found to be 29.8%. Other earlier studies in Africa reported that the prevalence of AUD ranges from 17 to 39.4% in Nigeria [8][9][10], 1.4 to 33% in Uganda [11][12][13][14], 6.6 to 48.5% in South Africa [15][16][17][18], 5.4 to 33% in Kenya [19][20][21][22], and 14.8% in Zambia [23]. There exists a scarcity of average data on alcohol use disorders in people with HIV in other African countries despite the high disease burden with people living with HIV (PLWHA) [24].…”
Section: Introductionmentioning
confidence: 99%